BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25837929)

  • 21. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
    Tian L; Chen C; Guo Y; Zhang F; Mi J; Feng Q; Lin S; Xi N; Tian J; Yu L; Chen Y; Cao M; Lai C; Fan J; Zhang Y; Chen G
    Neoplasia; 2021 Jul; 23(7):643-652. PubMed ID: 34126361
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
    Ruiz van Haperen VW; Veerman G; Eriksson S; Stegmann AP; Peters GJ
    Semin Oncol; 1995 Aug; 22(4 Suppl 11):35-41. PubMed ID: 7481843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
    Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
    Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
    Liang M; Zhao T; Ma L; Guo Y
    Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
    Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
    Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
    Yao J; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Yang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Dec; 27(12):721-6. PubMed ID: 16483481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
    Andersson R; Aho U; Nilsson BI; Peters GJ; Pastor-Anglada M; Rasch W; Sandvold ML
    Scand J Gastroenterol; 2009; 44(7):782-6. PubMed ID: 19214867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of RRM1 and its effect on chemoresistance in pancreatic cancer.
    Lin X; Tan Y; Pan L; Tian Z; Lin L; Su M; Ou G; Chen Y
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):237-251. PubMed ID: 38040978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
    Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
    BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
    Jung CP; Motwani MV; Schwartz GK
    Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
    Cory AH; Hertel LW; Kroin JS; Cory JG
    Oncol Res; 1993; 5(2):59-63. PubMed ID: 8364254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
    Samulitis BK; Pond KW; Pond E; Cress AE; Patel H; Wisner L; Patel C; Dorr RT; Landowski TH
    Cancer Biol Ther; 2015; 16(1):43-51. PubMed ID: 25485960
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
    Guillermet-Guibert J; Davenne L; Pchejetski D; Saint-Laurent N; Brizuela L; Guilbeau-Frugier C; Delisle MB; Cuvillier O; Susini C; Bousquet C
    Mol Cancer Ther; 2009 Apr; 8(4):809-20. PubMed ID: 19372554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
    Wonganan P; Chung WG; Zhu S; Kiguchi K; Digiovanni J; Cui Z
    Cancer Biol Ther; 2012 Aug; 13(10):908-14. PubMed ID: 22785206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.
    Chen Z; Zhou J; Zhang Y; Bepler G
    Biochem Biophys Res Commun; 2011 Sep; 413(2):383-8. PubMed ID: 21893046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.